SciClone Pharmaceuticals, Inc. announced the appointment of Hong Zhao as Chief Executive Officer, China Operations. Mr. Zhao is an accomplished, respected pharmaceutical industry executive with more than 20 years of experience in leading the commercial operations, market expansion and growth of multi-national companies in China. Mr. Zhao joins SciClone from Simcere Pharmaceutical Group, where he served as Executive Vice President, responsible for all business operations, including leading a sizeable sales team and managing multiple business units, and had direct reporting responsibility for medical affairs, market access, marketing and sales operations, training and personnel development.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.22 HKD | +0.11% | +1.00% | +30.89% |
04-18 | Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31 | MT |
04-01 | SciClone Pharmaceuticals Logs 31% Increase in 2023 Profit | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+30.89% | 1.42B | |
-2.61% | 89.08B | |
+3.55% | 40.9B | |
-14.40% | 32.25B | |
+55.89% | 25.14B | |
-15.96% | 15.39B | |
-15.50% | 11.91B | |
-41.29% | 11.89B | |
-11.75% | 11.64B | |
+7.87% | 9.03B |
- Stock Market
- Equities
- 6600 Stock
- News SciClone Pharmaceuticals (Holdings) Limited
- SciClone Pharmaceuticals, Inc. Appoints Hong Zhao as Chief Executive Officer, China Operations